ARCHIVES

Institutions Required To Review For Bias under PHS Proposal

This article is from The Cancer Letter archive.

Vol. 20 No. 29 | July 22, 1994

Download PDF Visit The Full Archive

Related Articles

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

August 26, 2005

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012

XIIIth International Cancer Congress in Seattle Drawing Record Numbers Or Top Scientific Program

July 30, 1982

New NCI advisory Boards Appointed, Begin Review Of NCI Programs

March 29, 1996

Pazdur: Registration Trials Run By Groups Need Same Rigor As Industry Trials

March 25, 2011

FDA Publishes Parallel Track Rules, Accelerated Drug Approval Initiative

April 25, 1992